erlotinib

erlotinib is a medication used to treat non-small cell lung cancer and pancreatic cancer, developed by Hoffmann-La Roche and marketed by Genentech and Roche Holding. It is a type of tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), which is often overexpressed in certain types of cancer, including lung cancer and breast cancer, as researched by National Cancer Institute and American Cancer Society. The development of erlotinib was influenced by the work of Robert Weinberg and Charles Sawyers, who studied the role of EGFR in cancer, and was approved by the US Food and Drug Administration (FDA) in 2004, following clinical trials conducted by Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Introduction

Erlotinib is used in combination with gemcitabine to treat pancreatic cancer that has spread to other parts of the body, as studied by Johns Hopkins University and University of California, Los Angeles. It is also used as a single agent to treat non-small cell lung cancer that has spread to other parts of the body and has not responded to chemotherapy, as researched by National Institutes of Health and Cancer Research UK. The use of erlotinib has been influenced by the work of Vincent DeVita and Samuel Hellman, who developed the concept of adjuvant therapy, and has been approved by regulatory agencies such as the European Medicines Agency and Pharmaceuticals and Medical Devices Agency.

Mechanism_of_action

Erlotinib works by inhibiting the activity of the epidermal growth factor receptor (EGFR), which is a type of tyrosine kinase receptor that plays a critical role in the growth and spread of cancer cells, as studied by Stanford University and University of Texas Southwestern Medical Center. The inhibition of EGFR by erlotinib prevents the activation of downstream signaling pathways that promote cell growth and survival, leading to the death of cancer cells, as researched by Harvard University and University of Pennsylvania. The mechanism of action of erlotinib is similar to that of other tyrosine kinase inhibitors, such as gefitinib and afatinib, which are used to treat similar types of cancer, including colorectal cancer and head and neck cancer, as developed by AstraZeneca and Boehringer Ingelheim.

Medical_uses

Erlotinib is used to treat a variety of types of cancer, including non-small cell lung cancer, pancreatic cancer, and breast cancer, as studied by MD Anderson Cancer Center and University of Chicago. It is often used in combination with other medications, such as chemotherapy and radiation therapy, to treat cancer that has spread to other parts of the body, as researched by National Cancer Institute and American Society of Clinical Oncology. The use of erlotinib has been influenced by the work of James Allison and Tasuku Honjo, who developed the concept of immunotherapy, and has been approved by regulatory agencies such as the US Food and Drug Administration and European Medicines Agency.

Side_effects

Erlotinib can cause a variety of side effects, including diarrhea, fatigue, and rash, as reported by MedlinePlus and Mayo Clinic. It can also cause more serious side effects, such as interstitial lung disease and gastrointestinal perforation, as studied by Cleveland Clinic and University of California, San Francisco. The side effects of erlotinib are similar to those of other tyrosine kinase inhibitors, such as gefitinib and afatinib, which can cause similar side effects, including liver damage and kidney damage, as developed by Pfizer and Merck & Co.

Pharmacology

Erlotinib is a small molecule that is taken orally, as developed by Hoffmann-La Roche and marketed by Genentech and Roche Holding. It is absorbed into the bloodstream and distributed to tissues throughout the body, where it inhibits the activity of the epidermal growth factor receptor (EGFR), as researched by University of California, Los Angeles and Johns Hopkins University. The pharmacology of erlotinib is similar to that of other tyrosine kinase inhibitors, such as gefitinib and afatinib, which are used to treat similar types of cancer, including colorectal cancer and head and neck cancer, as studied by Stanford University and University of Texas Southwestern Medical Center.

History

Erlotinib was first approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of non-small cell lung cancer that has spread to other parts of the body, as reported by FDA and National Cancer Institute. It was later approved for the treatment of pancreatic cancer in 2005, as studied by American Cancer Society and Cancer Research UK. The development of erlotinib was influenced by the work of Robert Weinberg and Charles Sawyers, who studied the role of EGFR in cancer, and was developed by Hoffmann-La Roche and marketed by Genentech and Roche Holding, in collaboration with Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Category:Medications